Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 3
2008 1
2010 1
2011 2
2012 1
2019 4
2020 3
2021 3
2022 5
2023 3
2024 3
2025 3
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Cetuximab-induced acne.
Molinari E, De Quatrebarbes J, André T, Aractingi S. Molinari E, et al. Among authors: de quatrebarbes j. Dermatology. 2005;211(4):330-3. doi: 10.1159/000088502. Dermatology. 2005. PMID: 16286741 Clinical Trial.
When to stop immunotherapy for advanced melanoma: the emulated target trials.
Amiot M, Mortier L, Dalle S, Dereure O, Dalac S, Dutriaux C, Leccia MT, Maubec E, Arnault JP, Brunet-Possenti F, De Quatrebarbes J, Granel-Brocard F, Gaudy-Marqueste C, Pages C, Stoebner PE, Saiag P, Lesimple T, Dupuy A, Legoupil D, Montaudié H, Oriano B, Lebbe C, Porcher R. Amiot M, et al. Among authors: de quatrebarbes j. EClinicalMedicine. 2024 Dec 4;78:102960. doi: 10.1016/j.eclinm.2024.102960. eCollection 2024 Dec. EClinicalMedicine. 2024. PMID: 39717261 Free PMC article.
[Bullous pemphigoid].
de Quatrebarbes J, Joly P. de Quatrebarbes J, et al. Rev Prat. 2005 Jun 15;55(11):1165-8. Rev Prat. 2005. PMID: 16164060 Review. French.
Atypical nodular panniculitis.
Picard D, de Quatrebarbes J, Gueit I, Joly P. Picard D, et al. Among authors: de quatrebarbes j. Int J Infect Dis. 2011 Apr;15(4):e289-90. doi: 10.1016/j.ijid.2010.12.007. Epub 2011 Feb 1. Int J Infect Dis. 2011. PMID: 21288751 Free article.
The efficacy and safety of first-line metastatic melanoma treatment with ipilimumab + nivolumab vs. nivolumab in a real-world setting.
Billard K, Mortier L, Dereure O, Dalac S, Montaudié H, Legoupil D, Dutriaux C, De Quatrebarbes J, Maubec E, Leccia MT, Granel-Brocard F, Brunet-Possenti F, Arnault JP, Gaudy-Marqueste C, Pages C, Saiag P, L'Orphelin JM, Zehou O, Lesimple T, Allayous C, Porcher R, Oriano B, Dalle S, Lebbé C. Billard K, et al. Among authors: de quatrebarbes j. Br J Dermatol. 2025 May 19;192(6):1096-1105. doi: 10.1093/bjd/ljae470. Br J Dermatol. 2025. PMID: 39605282
Cost-Effectiveness Analysis of Sequential Treatment Strategies for Advanced Melanoma in Real Life in France.
Kandel M, Bardet A, Dalle S, Allayous C, Mortier L, Guillot B, Dutriaux C, Leccia MT, Dalac S, Montaudie H, Saiag P, Legoupil D, Brunet-Possenti F, Arnault JP, Quatrebarbes J, Beylot-Barry M, Maubec E, Lesimple T, Aubin F, Grob JJ, Granel-Brocard F, Stoebner PE, Dupuy A, Dreno B, Michiels S, Lebbe C, Borget I. Kandel M, et al. Among authors: quatrebarbes j. Curr Oncol. 2022 Nov 27;29(12):9255-9270. doi: 10.3390/curroncol29120725. Curr Oncol. 2022. PMID: 36547139 Free PMC article.
Combined Nivolumab and Ipilimumab in Octogenarian and Nonagenarian Melanoma Patients.
Reichert C, Baldini C, Mezghani S, Maubec E, Longvert C, Mortier L, Quereux G, Jannic A, Machet L, de Quatrebarbes J, Nardin C, Beneton N, Amini Adle M, Funck-Brentano E, Descamps V, Hachon L, Malissen N, Baroudjian B, Brunet-Possenti F; Groupe de Cancérologie Cutanée. Reichert C, et al. Among authors: de quatrebarbes j. Cancers (Basel). 2023 Aug 30;15(17):4330. doi: 10.3390/cancers15174330. Cancers (Basel). 2023. PMID: 37686606 Free PMC article.
Quality-of-life assessment in French patients with metastatic melanoma in real life.
Kandel M, Dalle S, Bardet A, Allayous C, Mortier L, Dutriaux C, Guillot B, Leccia MT, Dalac S, Legoupil D, Saiag P, Montaudie H, Arnault JP, Brunet-Possenti F, Grob JJ, DeQuatrebarbes J, Beylot-Barry M, Lesimple T, Aubin F, Maubec E, Granel-Brocard F, Stoebner PE, Dupuy A, Dreno B, Michiels S, Lebbe C, Borget I. Kandel M, et al. Cancer. 2020 Feb 1;126(3):611-618. doi: 10.1002/cncr.32554. Epub 2019 Oct 22. Cancer. 2020. PMID: 31639198 Free article.
Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case-control study.
Plaçais L, Dalle S, Dereure O, Trabelsi S, Dalac S, Legoupil D, Montaudié H, Arnault JP, De Quatrebarbes J, Saiag P, Brunet-Possenti F, Lesimple T, Maubec E, Aubin F, Granel-Brocard F, Grob JJ, Stoebner PE, Allayous C, Oriano B, Dutriaux C, Mortier L, Lebbe C. Plaçais L, et al. Among authors: de quatrebarbes j. Ann Rheum Dis. 2022 Oct;81(10):1445-1452. doi: 10.1136/ard-2022-222186. Epub 2022 Jul 4. Ann Rheum Dis. 2022. PMID: 35788496 Free article.
Non-V600E/K BRAF Mutations in Metastatic Melanoma: Molecular Description, Frequency, and Effectiveness of Targeted Therapy in a Large National Cohort.
Girod M, Dalle S, Mortier L, Dalac S, Leccia MT, Dutriaux C, Montaudié H, de Quatrebarbes J, Lesimple T, Brunet-Possenti F, Saiag P, Maubec E, Legoupil D, Stoebner PE, Arnault JP, Lefevre W, Lebbe C, Dereure O. Girod M, et al. Among authors: de quatrebarbes j. JCO Precis Oncol. 2022 Nov;6:e2200075. doi: 10.1200/PO.22.00075. JCO Precis Oncol. 2022. PMID: 36356284
27 results